Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.

You may also be interested in...



With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results

Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.

Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing

Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.

Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing

Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel